A trial of a dual-target CAR-T therapy for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of blood cancer like non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not improved with treatment.
- You are well enough to carry out daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have not had certain other cancer treatments too recently.
- You are not pregnant or breastfeeding, and you do not have active hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CART cells) that are engineered to find and destroy cancer cells in certain types of B-cell blood cancers. It might help if standard treatments have stopped working.
This early-stage trial tests a new type of immune cell therapy (LVIVO-TaVec122) designed to fight back against B-cell lymphomas and leukemias that have stopped responding to previous treatments. The goal is to see if this therapy is safe and how well it works.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR-T therapy designed to target and kill CD20-positive cancer cells in people with blood cancers like B-cell lymphoma or lymphocytic leukemia. It is an early study to see if this approach is safe and works.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers found on B-cell lymphomas that haven't responded to standard treatments. The therapy uses nanobodies—smaller immune proteins—to help your own cells recognize and kill cancer cells.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.